Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Line Items]
Provision for income taxes	$ 0	$ 0
Net operating loss carryforwards	3,604,179	$ 1,843,000
Research and development and orphan drug credits	$ 6,300,000
Net operating loss carryforwards term	20 years
Net operating loss carryforwards expiration beginning year	2022
Corporate federal income tax rate	21.00%	34.00%
Reduction in deferred tax assets		$ 8,200,000
State
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 15,900,000